Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Myriad Genetics Inc.

    NASDAQ: MYGN · Real-Time Price · USD
    5.04
    -0.15 (-2.89%)
    At close: Jun 13, 2025, 3:59 PM
    5.01
    -0.52%
    After-hours: Jun 13, 2025, 07:07 PM EDT

    Myriad Genetics Statistics

    Share Statistics

    Myriad Genetics has 92.18M shares outstanding. The number of shares has increased by 0.89% in one year.

    Shares Outstanding

    n/a
    		 92.18M

    Shares Change (YoY)

    n/a
    		 0.89%

    Shares Change (QoQ)

    n/a
    		 0.3%

    Owned by Institutions (%)

    n/a
    		 99.99%

    Shares Floating

    n/a
    		 87.74M

    Failed to Deliver (FTD) Shares

    n/a
    		 60

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 8.78M, so 9.52% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 8.78M

    Short % of Shares Out

    n/a
    		 9.52%

    Short % of Float

    n/a
    		 13.44%

    Short Ratio (days to cover)

    n/a
    		 4.08

    Valuation Ratios

    The PE ratio is -6.02 and the forward PE ratio is 34.5. Myriad Genetics's PEG ratio is -0.05.

    PE Ratio

    n/a
    		 -6.02

    Forward PE

    n/a
    		 34.5

    PS Ratio

    n/a
    		 2.1

    Forward PS

    n/a
    		 0.5

    PB Ratio

    n/a
    		 2.02

    P/FCF Ratio

    n/a
    		 -8.6

    PEG Ratio

    n/a
    		 -0.05
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Myriad Genetics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.19.

    Current Ratio

    n/a
    		 2.01

    Quick Ratio

    n/a
    		 1.87

    Debt / Equity

    n/a
    		 0.19

    Debt / EBITDA

    n/a
    		 -0.82

    Debt / FCF

    n/a
    		 -0.83

    Interest Coverage

    n/a
    		 -88.76

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $278,962.96

    Profits Per Employee

    n/a
    		 $-97,518.52

    Employee Count

    n/a
    		 2,700

    Asset Turnover

    n/a
    		 0.66

    Inventory Turnover

    n/a
    		 10.74

    Taxes

    Income Tax

    n/a
    		 1.1M

    Effective Tax Rate

    n/a
    		 -0.42%

    Stock Price Statistics

    The stock price has increased by -78.28% in the last 52 weeks. The beta is 1.85, so Myriad Genetics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.85

    52-Week Price Change

    n/a
    		 -78.28%

    50-Day Moving Average

    n/a
    		 5.96

    200-Day Moving Average

    n/a
    		 14.36

    Relative Strength Index (RSI)

    n/a
    		 47.7

    Average Volume (20 Days)

    n/a
    		 2,124,287

    Income Statement

    In the last 12 months, Myriad Genetics had revenue of 753.2M and earned -263.3M in profits. Earnings per share was -3.18.

    Revenue

    n/a
    		 753.2M

    Gross Profit

    n/a
    		 517M

    Operating Income

    n/a
    		 -257.4M

    Net Income

    n/a
    		 -263.3M

    EBITDA

    n/a
    		 -186.1M

    EBIT

    n/a
    		 -259.3M

    Earnings Per Share (EPS)

    n/a
    		 -3.18
    Full Income Statement

    Balance Sheet

    The company has 132.1M in cash and 152.1M in debt, giving a net cash position of -20M.

    Cash & Cash Equivalents

    n/a
    		 132.1M

    Total Debt

    n/a
    		 152.1M

    Net Cash

    n/a
    		 -20M

    Retained Earnings

    n/a
    		 -629.5M

    Total Assets

    n/a
    		 1.08B

    Working Capital

    n/a
    		 138.9M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -110.9M and capital expenditures -73.3M, giving a free cash flow of -184.2M.

    Operating Cash Flow

    n/a
    		 -110.9M

    Capital Expenditures

    n/a
    		 -73.3M

    Free Cash Flow

    n/a
    		 -184.2M

    FCF Per Share

    n/a
    		 -2.22
    Full Cash Flow Statement

    Margins

    Gross margin is 68.64%, with operating and profit margins of -34.17% and -34.96%.

    Gross Margin

    n/a
    		 68.64%

    Operating Margin

    n/a
    		 -34.17%

    Pretax Margin

    n/a
    		 -34.81%

    Profit Margin

    n/a
    		 -34.96%

    EBITDA Margin

    n/a
    		 -24.71%

    EBIT Margin

    n/a
    		 -34.17%

    FCF Margin

    n/a
    		 -24.46%

    Dividends & Yields

    MYGN does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for MYGN is $11, which is 118.3% higher than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $11

    Price Target Difference

    n/a
    		 118.3%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 14
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 26, 2009. It was a forward split with a ratio of 2:1.

    Last Split Date

    n/a
    		 Mar 26, 2009

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 2:1

    Scores

    Altman Z-Score

    n/a
    		 0.31

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist